ScholarWorks@Dongguk University: Kim, Dong eog

Detailed Information

Kim, Dong eog (김동억)

Graduate School (Department of Medicine)

Research Area

Tel 031-961-7210
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

stroke:23||Stroke:18||ischemic stroke:17||cerebral infarction:11||Acute ischemic stroke:10||Ischemic stroke:9||acute ischemic stroke:9||atrial fibrillation:8||aspirin:7||atherosclerosis:7||magnetic resonance imaging:6||thrombolysis:6||recurrence:5||Atrial fibrillation:5||clopidogrel:5||prognosis:5||Magnetic resonance imaging:5||molecular imaging:4||Ischemic Stroke:4||Thrombolytic therapy:4||Molecular imaging:4||myocardial infarction:4||LDLcholesterol:3||Early vascular outcome:3||heart rate:3||outcome:3||outcome assessment:3||Prognosis:3||propensity score:3||Depression:3||Cerebral infarction:3||computed tomography:3||Hypertension:3||leukoaraiosis:3||Atherosclerosis:3||Deep learning:3||endovascular treatment:3||microCT:3||mortality:3||Thrombolysis:3||white matter hyperintensities:3||blood pressure:3||gold nanoparticles:2||bloodbrain barrier:2||South Korea:2||Body mass index:2||Anger:2||Nanomedicine:2||Cerebral infarct:2||Outcome assessment:2||Asia:2||direct thrombus imaging:2||large artery atherosclerosis:2||largevessel occlusion:2||Computed tomography:2||prevention:2||Thrombectomy:2||prediction:2||mild stroke:2||MMP9:2||thrombectomy:2||Intravenous thrombolysis:2||Anticoagulants:2||thrombus imaging:2||early neurological deterioration:2||gold nanoparticle:2||Arteriosclerosis:2||tissuetype plasminogen activator:2||perfusion imaging:2||Stroke subtype:2||Acute stroke:2||endovascular recanalization:2||Matrix metalloproteinase:2||Thrombus imaging:2||Transient:2||cohort study:2||Ischemic Attack:2||registries:2||Heart failure:2||risk factors:2||Tissue plasminogen activator:2||Cardiovascular diseases:2||hypertension:2||acute minor stroke:2||secondary prevention:2||Diffusion magnetic resonance imaging:2||death:2||Intravital two photon microscopy:1||Iodinated contrast agents:1||Ischaemic stroke:1||Issue 115:1||Korea:1||LDLC:1||LDL/HDL ratio:1||Large artery stenoocclusion:1||Lateral medullary syndrome:1||Left atrial appendage closure:1||Lipid paradox:1||Lipid ratio:1||MRI:1||Magnetic Resonance Imaging:1||Medical complications:1||Medicine:1||Menkes disease:1||Mild stroke:1||Minor Ischemic Stroke:1||Modified Rankin Scale:1||Monocyte deficiency:1||NIHSS:1||Nanoparticle:1||Nerinetide:1||Neural stem cell:1||Neurogenesis:1||Neurovascular:1||Nontraditional lipid profiles:1||Obesity paradox:1||Oral anticoagulant:1||Outcome:1||Outcome after stroke:1||Outcomes:1||Ovariectomy:1||Oxiracetam:1||PSD95:1||Patent foramen ovale closure:1||Penumbra:1||Physician training:1||Plaque:1||Plaque imaging:1||Platelet aggregation inhibitors:1||Polycythemia Vera:1||Positronemission tomography:1||Preceding intravenous thrombolysis:1||Prophylaxis:1||Protein engineering:1||Proteolytic enzymes:1||Recurrent event:1||Reference standards:1||Registries:1||Reperfusion:1||Republic of Korea:1||Residual cardiovascular risk:1||Risk score:1||Sex:1||Silent brain infarction:1||Silicacoated gold nanoparticle:1||Small vessel occlusion:1||Statin pretreatment:1||Statins:1||Statistics:1||Stem cell imaging:1||Stenosis:1||Stroke Recurrence:1||Stroke imaging:1||Stroke progression:1||Stroke recurrence:1||Stroke registry:1||Stroke severity:1||Subgroup analysis:1||Therapeutic benefit:1||Thrombinactivatable fluorescent probe:1||Tissueplasminogen activator:1||UVvis spectroscopy:1||Underweight:1||Utilization:1||Vascular cognitive impairment:1||Vascular outcome:1||Vascular surgery:1||Vascularization:1||Venous thromboembolism:1||Vulnerable plaque:1||Waist circumference:1||Xray Computed Tomography:1||acute isc hemic stroke:1||acute ischaemic stroke:1||acute myocardial infarction:1||acute stroke:1||advanced treatments:1||age:1||air pollution:1||amyloid deposition:1||anemia:1||angiography:1||anticoagulation:1||antiplatelet:1||antiplatelet agents:1||antiplatelet drugs:1||antiplatelets:1||apolipoproteins:1||arrhythmias, cardiac:1||arterial thrombosis:1||assessment, patient outcome:1||asymmetry:1||atorvastatin:1||basilar artery:1||beta blocker:1||bioorthogonal click chemistry:1||brain frailty:1||brain ischemia:1||brain macrobleed:1||brain stroke:1||carotid artery occlusion:1||carotid intima media thickness:1||carotid plaque:1||cathepsinB:1||cerebral microinfarct:1||cholinergic fibers:1||clinical inertia:1||clinical outcomes:1||clinical trial:1||clopidogrelaspirin:1||cohort studies:1||collateral circulation:1||comparative effectiveness research:1||complete blood count (CBC):1||computed tomography angiography:1||connectome:1||coronary heart disease:1||deep learning:1||deeplearning algorithm:1||dementia:1||demography:1||depression:1||diabetes:1||diagnosis:1||disparity:1||dissection:1||dripandship:1||dual antiplatelet treatment:1||dual antiplatelets:1||dualmodal imaging:1||early vascular outcomes:1||embolic stroke:1||embolic stroke of undetermined source:1||embolism:1||endovascular therapy:1||epidemiology:1||escitalopram:1||fibrintargeted gold nanoparticle:1||genedepression:1||gintonin:1||glial scar formation:1||global longitudinal peak strain:1||glucocorticoids:1||glycated hemoglobin (hbA1c):1||glycol chitosan:1||groupbased trajectory model:1||guideline adherence:1||health services research:1||hematopoietic stem cells:1||hemoglobins:1||hemorrhage:1||hemorrhagic transformation:1||hemostatic:1||heparin:1||history of intracerebral hemorrhage:1||hospital performance:1||humans:1||hyperintense vessel sign:1||imaging probe:1||incidence:1||inflammation:1||infusion:1||interventional neuroradiology:1||intima:1||intraarterial:1||intracranial atherosclerosis:1||intracranial hemorrhage (ICH):1||intracranial stenosis:1||intravenous thrombolysis:1||intravital imaging:1||iopromide:1||ischaemic stroke:1||ischemic:1||ischemic attack, transient:1||lacunar infarct:1||lacunar stroke:1||lacunes:1||late‐presenting stroke:1||left atrial volume index:1||lipids and lipoproteins:1||lipopolysaccharide:1||low NIHSS score:1||lowdose tPA:1||lymphocyte:1||machine learning:1||macrophage:1||magnetic resonance angiography:1||magnetic resonance image:1||major vascular event:1||management:1||media thickness:1||metabolic engineering:1||microCT:1||microbleeds:1||migraine:1||motor recovery:1||multicenter registry:1||multicenter studies:1||nearinfrared fluorescent imaging:1||neural network:1||neural networks:1||neural pathways:1||neuroimaging:1||neuroprotective:1||nitric oxide synthase:1||nonminor stroke:1||oligemia:1||particulate matter:1||pharmacokinetics:1||photodynamic therapy:1||photosensitizer:1||plateletderived growth factor:1||prestroke glycemic status:1||proportional hazards models:1||prospective cohort study:1||prospective studies:1||proteasemediated theranostic agent:1||pulse pressure:1||quality:1||randomized:1||randomized clinical trial:1||reactive astrocyte:1||risk:1||risk score:1||rosuvastatin:1||safety:1||seconadry stroke prevention:1||secular trend:1||segmentation algorithm:1||serotonin:1||small vessel disease:1||speckletracking imaging echocardiography:1||staining:1||statin:1||stem cell tracking:1||stroke care:1||stroke etiology:1||stroke mechanism:1||stroke recurrence:1||stroke registry:1||stroke subtype:1||strongly annotated dataset:1||symptomatic hemorrhagic transformation:1||syndrome:1||tMCAO:1||temporal trends:1||thrombus evolution:1||time in therapeutic range:1||time to treatment:1||timetotreatment:1||topographic brain mapping:1||transient ischemic attack:1||treatment:1||treatment duration:1||treatment intensification:1||trends:1||triage:1||tumor targeting:1||ultrasonography:1||vascular cognitive impairment:1||vascular death:1||vascular event:1||warfarin:1||weighted ensemble model:1||white blood cell (WBC) differential count:1||white matter disease:1||whitematter hyperintensity:1||.:1||young adult:1||2,3,5Triphenyltetrazolium chloride:1||3 to 4.5hour time window:1||ASPECTS:1||ATP7A:1||Abdominal obesity:1||Acute stroke therapy:1||Admission hyperglycemia:1||Admission route:1||Algorithm:1||Angiography:1||Anticoagulation:1||Antiplatelet:1||Antiplatelet drugs:1||Antithrombotic:1||Apoptosis imaging:1||Artificial intelligence:1||Atheroma:1||Atherosclerotic stroke:1||Behavior change:1||Blood pressure:1||Brain Infarction: Recovery of Function:1||CRCSK:1||CTcontrast agent:1||Cancer:1||Cardioembolism:1||Cardiovascular disease:1||Case profile:1||Cerebral Infarction:1||Classification:1||Clinical trial:1||Comparative effectiveness research:1||Cytokine:1||Cytokines:1||DWIASPECTS:1||Deep vein thrombosis:1||Deglutition:1||Deglutition disorders:1||Demography:1||Dendrimers:1||Diabetes mellitus:1||Diffusionweighted image:1||Direct thrombus imaging:1||Disparity:1||Domain adaptation:1||Drug Repurposing:1||Dual antiplatelet therapy:1||Dual optical/CT imaging:1||Dyslipidemia:1||END management:1||Early neurologic deterioration:1||Elderly:1||Emotional incontinence:1||Emotions:1||Endovascular Treatment:1||Endovascular therapy:1||Endovascular treatment:1||Escitalopram:1||Event Outcome:1||Exercise:1||Exercise training:1||Extracranial:1||FDGPET/CT:1||FHL2 (Four And A Half LIM Domains 2):1||Fracture:1||Functional MRI:1||Functional outcome:1||Futile reperfusion:1||GSK3:1||Gastrointestinal bleeding:1||Greenchannel autofluorescence imaging:1||HDAC:1||Hippocampus:1||Hyperacute treatment:1||Imaging agents:1||In vivo imaging:1||Incidence:1||Infarct volume:1||Infarction:1||Inflammation imaging:1||Interhospital transfer:1||Intimamedial thickness:1||Intracranial:1||Intracranial arterial stenosis:1||Intracranial hemorrhages:1||Intravenous Thrombolysis:1||Intravenous recombinant tissue plasminogen activator:1||

RSS_1.0 RSS_2.0 ATOM_1.0

30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE